Explore Diseases Find Orgs Patient Assistance News Insights About

Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

Open rare disease resources — free, sourced, never gated.

Resources

Rare Disease Directory
Patient Organization Directory
Patient Assistance Programs
Rare Disease News
Clinical Trials
Research Publications

Legal

Privacy Policy
Terms of Service
Accessibility
About & Methodology
Contact

pediatric hepatocellular carcinoma News | Kisho

Not rare diseases news,
news about your rare disease.

Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.

News sourcesFDA·NIH·CDC·EMA·PubMed·Federal Register·NORD·EURORDIS·Global Genes·The Mighty·BioPharma Dive·BioSpace

Newsroom35 Trends

Daily Briefings

Showing news related to

pediatric hepatocellular carcinoma

35 articles

View Disease

pediatric hepatocellular carcinoma

Earlier

15 stories

hepatocellular carcinoma pediatric hepatocellular carcinoma+1 moreResearch

A case report highlights a collision tumor of hepatocellular carcinoma and cholangiocarcinoma demonstrating an excellent therapeutic response. This study contributes to the understanding of treatment outcomes for this rare tumor type.

hepatocellular carcinoma cholangiocarcinoma collision tumor with excellent therapeutic response a case report and literature review

PubMed Rare Disease·6 months ago·Read at source →

Original title: “Hepatocellular carcinoma-cholangiocarcinoma collision tumor with excellent therapeutic response: a case report and literature review.”

hepatocellular carcinoma pediatric hepatocellular carcinoma+1 moreResearch

A case report highlights a pathological complete response in a patient with advanced hepatocellular carcinoma and portal vein tumor thrombus after receiving a combination of transarterial chemoembolization (TACE), hepatic arterial infusion chemotherapy (HAIC), lenvatinib, and sintilimab. This finding may inform future treatment strategies for similar cases.

pathological complete response in advanced hepatocellular carcinoma with portal vein tumor thrombus following conversion therapy with tace haic lenvatinib and sintilimab a case report

PubMed Rare Disease·6 months ago·Read at source →

Original title: “Pathological Complete Response in Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Following Conversion Therapy With TACE, HAIC, Lenvatinib, and Sintilimab: A Case Report.”

hepatocellular carcinoma pediatric hepatocellular carcinoma+1 moreResearch

A systematic review and meta-analysis updates the understanding of hepatocellular carcinoma attributable to hepatitis B, hepatitis C, and other risk factors globally and regionally. This research provides critical insights into the epidemiology of liver cancer, which is essential for targeted interventions.

hepatocellular carcinoma attributable to hepatitis b hepatitis c and other risk factors at global regional and national levels an updated systematic review and meta analysis

PubMed Rare Disease·6 months ago·Read at source →

Original title: “Hepatocellular carcinoma attributable to hepatitis B, hepatitis C and other risk factors at global, regional and national levels: an updated systematic review and meta-analysis.”

hepatocellular carcinoma pediatric hepatocellular carcinoma+1 moreResearch

Recent research highlights the role of PFKFB4 in M2 macrophage polarization, which may influence the progression of hepatocellular carcinoma. This discovery could open new avenues for targeted therapies in liver cancer.

integrated analyses reveal a potential role for pfkfb4 in m2 macrophage polarization and hepatocellular carcinoma progression

PubMed Rare Disease·6 months ago·Read at source →

Original title: “Integrated analyses reveal a potential role for PFKFB4 in M2 macrophage polarization and hepatocellular carcinoma progression.”

idiopathic copper-associated cirrhosis cirrhosis of liver+1 moreResearch

A study published in PubMed highlights simultaneous variants in the TFAM and TJP2 genes in a child diagnosed with cirrhosis and hepatocellular carcinoma. This research may provide insights into the genetic underpinnings of these conditions.

simultaneous tfam and tjp2 variants in a child with cirrhosis and hepatocellular carcinoma

PubMed Rare Disease·6 months ago·Read at source →

Original title: “Simultaneous TFAM and TJP2 Variants in a Child With Cirrhosis and Hepatocellular Carcinoma.”

hepatocellular carcinoma pediatric hepatocellular carcinoma+1 moreTrials & approvals

CatalYm initiates a phase 2b trial of visugromab for second-line treatment of hepatocellular carcinoma, expanding its development in this challenging cancer space. This trial aims to evaluate the efficacy of the antibody in patients who have not responded to prior therapies.

Study expands development of the antibody into hepatocellular carcinoma

Pharma Times·7 months ago·Read at source →

Original title: “CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment”

hepatocellular carcinoma pediatric hepatocellular carcinoma+1 moreResearch

A multicenter French study investigates the role of alpha-1 antitrypsin deficiency alleles in non-cirrhotic hepatocellular carcinoma. The findings contribute to understanding the genetic factors influencing this cancer type.

alpha 1 antitrypsin deficiency alleles in non cirrhotic hepatocellular carcinoma insights from a multicenter french cohort

PubMed Rare Disease·7 months ago·Read at source →

Original title: “Alpha-1 Antitrypsin Deficiency Alleles in Non-Cirrhotic Hepatocellular Carcinoma: Insights from a Multicenter French Cohort.”

hepatocellular carcinoma pediatric hepatocellular carcinoma+1 moreResearch

A new study reveals that WBC-HBP dissociation can uncover occult xanthogranulomatous inflammation that mimics hepatocellular carcinoma in diabetic patients. This discovery may impact diagnostic approaches in this patient population.

wbc hbp dissociation unveils occult xanthogranulomatous inflammation mimicking hepatocellular carcinoma in diabetic patients

PubMed Rare Disease·8 months ago·Read at source →

Original title: “"WBC-HBP Dissociation" Unveils Occult Xanthogranulomatous Inflammation Mimicking Hepatocellular Carcinoma in Diabetic Patients.”

hepatocellular carcinoma pediatric hepatocellular carcinoma+1 moreResearch

A 20-year retrospective study highlights the increasing burden of non-B non-C hepatocellular carcinoma, emphasizing the need for updated surveillance strategies and prognostic assessments. The findings suggest significant shifts in etiology that could impact patient management.

impact of etiological shifts and the rising burden of non b non c hepatocellular carcinoma on surveillance and prognosis insights from a 20 year retrospective observational study

PubMed Rare Disease·8 months ago·Read at source →

Original title: “Impact of Etiological Shifts and the Rising Burden of Non-B Non-C Hepatocellular Carcinoma on Surveillance and Prognosis: Insights From a 20-Year Retrospective Observational Study.”

hepatocellular carcinoma pediatric hepatocellular carcinoma+1 moreResearch

A study published in PubMed highlights that age alone should not limit the use of atezolizumab and bevacizumab in treating hepatocellular carcinoma in very elderly patients, except for those with ALBI Grade 3. This finding could influence treatment decisions for older patients with this cancer type.

atezolizumab bevacizumab in very elderly with hepatocellular carcinoma age alone is not a limiting factor except in albi grade 3

PubMed Rare Disease·8 months ago·Read at source →

Original title: “Atezolizumab-Bevacizumab in Very Elderly With Hepatocellular Carcinoma: Age Alone Is Not a Limiting Factor Except in ALBI Grade 3.”

hepatocellular carcinoma pediatric hepatocellular carcinoma+1 moreResearch

Research highlights how BRD9 recognizes lactate-induced H3K18 lactylation, contributing to oncogenic chromatin remodeling in hepatocellular carcinoma. This discovery may open new avenues for targeted therapies in liver cancer.

brd9 recognizes lactate induced h3k18 lactylation to drive oncogenic chromatin remodeling in hepatocellular carcinoma

PubMed Rare Disease·8 months ago·Read at source →

Original title: “BRD9 recognizes lactate-induced H3K18 lactylation to drive oncogenic chromatin remodeling in hepatocellular carcinoma.”

hepatocellular carcinoma pediatric hepatocellular carcinoma+1 moreResearch

A recent case report highlights the association of hepatocellular carcinoma with hepatic sarcoidosis and Budd-Chiari syndrome. This review of literature provides insights into the complex interplay between these conditions, which may inform future research and clinical approaches.

hepatocellular carcinoma associated with hepatic sarcoidosis and budd chiari syndrome a case report and review of the literature

PubMed Rare Disease·8 months ago·Read at source →

Original title: “Hepatocellular Carcinoma Associated with Hepatic Sarcoidosis and Budd-Chiari Syndrome: A Case Report and Review of the Literature.”

hepatocellular carcinoma pediatric hepatocellular carcinoma+1 moreResearch

A case study reports complete remission in a patient with advanced hepatocellular carcinoma following sequential therapy with durvalumab and cabozantinib. This finding may provide insights into effective treatment strategies for this challenging cancer.

case of complete remission with durvalumab cabozantinib sequential therapy for advanced hepatocellular carcinoma

PubMed Rare Disease·9 months ago·Read at source →

Original title: “A case of complete remission with durvalumab-cabozantinib sequential therapy for advanced hepatocellular carcinoma.”

hepatocellular carcinoma pediatric hepatocellular carcinoma+1 moreResearch

A multicenter retrospective study investigates the efficacy of resection combined with hyperthermic intraperitoneal chemotherapy for treating spontaneously ruptured hepatocellular carcinoma. This approach may offer new insights into managing this aggressive cancer type.

resection combined with hyperthermic intraperitoneal chemotherapy in the treatment of spontaneously ruptured hepatocellular carcinoma a multicenter retrospective study

PubMed Rare Disease·9 months ago·Read at source →

Original title: “Resection combined with hyperthermic intraperitoneal chemotherapy in the treatment of spontaneously ruptured hepatocellular carcinoma: a multicenter retrospective study.”

hepatocellular carcinoma pediatric hepatocellular carcinoma+1 moreResearch

A study highlights a rare but fatal progression of hepatocellular carcinoma (HCC) to a right atrial tumor thrombus and inferior vena cava. This finding underscores the critical need for awareness and early detection in HCC cases.

rare but fatal outcome is hepatocellular carcinoma hcc progressing to the right atrial tumor thrombus and inferior vena cava

PubMed Rare Disease·9 months ago·Read at source →

Original title: “A rare but fatal outcome is hepatocellular carcinoma (HCC) progressing to the right atrial tumor thrombus and inferior vena cava.”

Previous2 / 2

Daily Briefings

Not rare diseases news,news about your rare disease.

Earlier

A case report highlights a collision tumor of hepatocellular carcinoma and cholangiocarcinoma demonstrating an excellent therapeutic response. This study contributes to the understanding of treatment outcomes for this rare tumor type.

Recent research highlights the role of PFKFB4 in M2 macrophage polarization, which may influence the progression of hepatocellular carcinoma. This discovery could open new avenues for targeted therapies in liver cancer.

A study published in PubMed highlights simultaneous variants in the TFAM and TJP2 genes in a child diagnosed with cirrhosis and hepatocellular carcinoma. This research may provide insights into the genetic underpinnings of these conditions.

CatalYm initiates a phase 2b trial of visugromab for second-line treatment of hepatocellular carcinoma, expanding its development in this challenging cancer space. This trial aims to evaluate the efficacy of the antibody in patients who have not responded to prior therapies.

A multicenter French study investigates the role of alpha-1 antitrypsin deficiency alleles in non-cirrhotic hepatocellular carcinoma. The findings contribute to understanding the genetic factors influencing this cancer type.

A new study reveals that WBC-HBP dissociation can uncover occult xanthogranulomatous inflammation that mimics hepatocellular carcinoma in diabetic patients. This discovery may impact diagnostic approaches in this patient population.

A 20-year retrospective study highlights the increasing burden of non-B non-C hepatocellular carcinoma, emphasizing the need for updated surveillance strategies and prognostic assessments. The findings suggest significant shifts in etiology that could impact patient management.

Research highlights how BRD9 recognizes lactate-induced H3K18 lactylation, contributing to oncogenic chromatin remodeling in hepatocellular carcinoma. This discovery may open new avenues for targeted therapies in liver cancer.

A recent case report highlights the association of hepatocellular carcinoma with hepatic sarcoidosis and Budd-Chiari syndrome. This review of literature provides insights into the complex interplay between these conditions, which may inform future research and clinical approaches.

A case study reports complete remission in a patient with advanced hepatocellular carcinoma following sequential therapy with durvalumab and cabozantinib. This finding may provide insights into effective treatment strategies for this challenging cancer.

A multicenter retrospective study investigates the efficacy of resection combined with hyperthermic intraperitoneal chemotherapy for treating spontaneously ruptured hepatocellular carcinoma. This approach may offer new insights into managing this aggressive cancer type.

A study highlights a rare but fatal progression of hepatocellular carcinoma (HCC) to a right atrial tumor thrombus and inferior vena cava. This finding underscores the critical need for awareness and early detection in HCC cases.

Not rare diseases news,
news about your rare disease.